Target and off-target effects of vibegron on smooth muscle contraction of human detrusor and prostate tissues
Abstract
Abstract Purpose The β 3 -agonist vibegron is available for treatment of storage symptoms, but in vitro data in human tissues are not yet available. Based on findings with mirabegron, mechanisms other than inhibition of voiding contractions in the detrusor may account for symptom improvements, and off-target effects in the prostate and bladder appear possible. Here, we examined vibegron effects in human detrusor and prostate tissues. Methods Detrusor and prostate tissues were obtained from radical cystectomy, radical prostatectomy and laser enucleation. Concentration response curves for agonists and frequence response curves for electric field stimulation (EFS) were examined in organ baths with 0.01, 0.1, 1 and 10 µM vibegron or vehicle control. Results In detrusor tissues, 10 µM vibegron reduced EFS-induced contractions by half, while no biologically relevant inhibitions occurred with lower concentrations or with carbachol- or methacholine-induced contractions. Pretensions before contractions were relaxed > 20% by 0.1–10 µM vibegron. EFS-induced contractions were halved by 10 µM vibegron in prostatectomized tissues, but unaffected by lower concentrations and in laser-enucleated prostate tissues. Additionally, 10 µM vibegron right-shifted concentration response curves and increased the EC 50 values for noradrenaline, phenylephrine and methoxamine in prostatectomized and laser-enucleated prostate tissues, while lower concentrations had no consistent effect. Conclusions…
Read the paper
Related studies
- Sarcopenia, sarcopenic overweight/obesity and risk of cardiovascular disease and cardiac arrhythmia: A cross-sectional study
- Workplace Violence Is Associated With Impaired Work Functioning in Nurses: An Italian Cross-Sectional Study
- Vagus Nerve Dysfunction in the Post-COVID-19 Condition: a pilot cross sectional study
- Association Between Metabolic Associated Fatty Liver Disease and Chronic Kidney Disease: A Cross-Sectional Study from NHANES 2017–2018
- Efficacy and safety of solifenacin succinate 10 mg once Daily: A multicenter, phase III, randomized, double-blind, placebo-controlled, parallel-group trial in patients with overactive bladder
- Association between triglyceride glucose‐body mass index and hypertension in Chinese adults: A cross‐sectional study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.